The rating view comes from China.
And still remains well behind actual share price.
Listing can come afterwards.
Outlook is Stable.
And also settles existing agreement.
After robust Q3 figures.
January-September profit exceeds annual profit of 2016.
Management expect strong competition.
Profit greatly beats expectations.
Regardless of rouble trouble.
Pharma firm buys treasury shares again for HUF 370 mn.
A report from the Portfolio Energy Investment Forum 2017 conference.
Share price approaches multi-year high.
Performance in quarterly terms not so stellar, though.
Signs exclusive distribution agreement with Prima-Temp.
General Counsel of Mol Group says they can wait.
Federal Supreme Court rejects Croatian appeal.
Rating agency affirms Mol's l-t IDR, with stable outlook.
State aid for Polyol Project is a go.
Long-term and short-term LC deposit ratings upgraded.